Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Pancreatic Adenocarcinoma Clinical Trial

Official title:

"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01365169
• Other study ID #: 2010-0955
• Secondary ID: NCI-2014-0246820
• Status: Recruiting
• Phase: N/A
• Start date: May 25, 2011
• Est. completion date: June 30, 2027

Study information

• Verified date: February 2024
• Source: M.D. Anderson Cancer Center
• Contact: Susan Peterson
• Phone: 713-792-8267
• Email: speterso[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.

Description:

PRIMARY OBJECTIVES: I. To explore the feasibility and acceptability in diverse samples of cancer patients of wireless collection and transmission of data for transfer into the open-source cyberinfrastructure (CI) called Cyberinfrastructure for Comparative Effectiveness Research (CYCORE). OUTLINE: Patients are assigned to 1 of 4 arms. ARM I (COLORECTAL CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a global positioning system (GPS) device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days. ARM II (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days. ARM III (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days. ARM IV (CANCER SURVIVORS THAT ARE CURRENT/FORMER SMOKERS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a carbon monoxide (CO) monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days. PANCREATIC CANCER STUDY (PCS): Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op. Technological Approach to Performance Status (TAPS) Study: Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 590
• Est. completion date: June 30, 2027
• Est. primary completion date: June 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of any stage I - IV colorectal cancer or recurrent colorectal cancer (Arm 1)
• Able to speak, read, and write in English (Pre-pilot phase, Arms 1-4)
• Able to provide informed consent (Pre-pilot phase, Arms 1-4, PCS study)
• Lives in the Houston area (Harris county or a contiguous county) (Pre-pilot phase)
• Eastern Cooperative Oncology Group (ECOG) status of 0 - 2, or self-reports being up and about more than 50% of waking hours and able to provide self-care (Arm 1)
• Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms 2 and 3)
• History of any cancer, other than non-melanoma skin cancer (Arm 4)
• Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm 4)
• Has a valid home address and functioning home telephone number (Arm 4)
• Lives in the Houston or surrounding area, or resides in this same area during the time period that coincides with this study (Arms 1-4)
• Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)
• Fluent in English (PCS study)
• Must have telephone access and agree to engage with research personnel using telephone (PCS study)
• Diagnosis of a metastatic or locally unresectable solid tumor (TAPS study)
• Fluent in English (TAPS study)
• Age 18 years or older (TAPS study)
• ECOG performance status score between 0-3 (TAPS study)

Exclusion Criteria:

• Major surgery in the past 8 weeks (Arms 1 and 4)
• Self-reports hypertension that is not being monitored by a physician and is not being managed with either medication, observation, or lifestyle change (Pre-pilot phase, Arms 1-3)
• Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)
• Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale (Pre-pilot phase, Arm 2)
• Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)
• Zubrod performance status > 2, or self-reports either not being up and about more than 50% of waking hours or unable to provide self-care (Arms 2 and 3)
• Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
• History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)
• Active substance use disorder (diagnosed or strongly suspected) (Arm 4)
• Currently enrolled in protocol 2014-0712 (PCS study)
• No home access to internet (PCS study)
• No home WiFi connection (PCS study)
• During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)
• Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study)
• Recent fracture or acute musculoskeletal injury that precludes the ability to fully bear weight on all 4 limbs in order to participate in an exercise intervention (PCS study)
• Poorly-controlled pain with a self-reported pain score of 7/10 at the time of enrollment (PCS study)
• Myopathic or rheumatologic disease that impacts physical function (PCS study)
• Has a pacemaker or other internal medical device, or reports being pregnant (PCS study)
• Currently enrolled in protocol 2017-0198 (PCS study)
• Demonstration of overt cognitive difficulty as demonstrated by not being clearly oriented to time or person or place (TAPS study)

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Islet Cell
• Carcinoma, Neuroendocrine
• Colorectal Neoplasms
• Head and Neck Neoplasms
• Laryngeal Neoplasms
• Malignant Head and Neck Neoplasm
• Malignant Neoplasm
• Metastatic Malignant Neoplasm in the Neck
• Metastatic Malignant Neoplasm in the Uterine Cervix
• Metastatic or Locally Unresectable Solid Tumor
• Mouth Neoplasms
• Nasopharyngeal Carcinoma
• Neoplasms
• Neoplasms, Second Primary
• Oropharyngeal Neoplasms
• Pancreatic Adenocarcinoma
• Pancreatic Neuroendocrine Carcinoma
• Recurrent Colorectal Carcinoma
• Salivary Gland Neoplasms
• Stage I Colorectal Cancer AJCC v6 and v7
• Stage I Hypopharyngeal Carcinoma AJCC v7
• Stage I Major Salivary Gland Cancer AJCC v7
• Stage I Nasopharyngeal Carcinoma AJCC v7
• Stage I Oral Cavity Cancer AJCC v6 and v7
• Stage I Oropharyngeal Carcinoma AJCC v6 and v7
• Stage II Colorectal Cancer AJCC v7
• Stage II Hypopharyngeal Carcinoma AJCC v6 and v7
• Stage II Major Salivary Gland Cancer AJCC v7
• Stage II Nasopharyngeal Carcinoma AJCC v7
• Stage II Oral Cavity Cancer AJCC v6 and v7
• Stage II Oropharyngeal Carcinoma AJCC v6 and v7
• Stage IIA Colorectal Cancer AJCC v7
• Stage IIB Colorectal Cancer AJCC v7
• Stage IIC Colorectal Cancer AJCC v7
• Stage III Colorectal Cancer AJCC v7
• Stage III Hypopharyngeal Carcinoma AJCC v7
• Stage III Laryngeal Cancer AJCC v6 and v7
• Stage III Major Salivary Gland Cancer AJCC v7
• Stage III Nasopharyngeal Carcinoma AJCC v7
• Stage III Oral Cavity Cancer AJCC v6 and v7
• Stage III Oropharyngeal Carcinoma AJCC v7
• Stage IIIA Colorectal Cancer AJCC v7
• Stage IIIB Colorectal Cancer AJCC v7
• Stage IIIC Colorectal Cancer AJCC v7
• Stage IV Colorectal Cancer AJCC v7
• Stage IVA Colorectal Cancer AJCC v7
• Stage IVA Hypopharyngeal Carcinoma AJCC v7
• Stage IVA Laryngeal Cancer AJCC v7
• Stage IVA Major Salivary Gland Cancer AJCC v7
• Stage IVA Nasopharyngeal Carcinoma AJCC v7
• Stage IVA Oral Cavity Cancer AJCC v6 and v7
• Stage IVA Oropharyngeal Carcinoma AJCC v7
• Stage IVB Colorectal Cancer AJCC v7
• Stage IVB Hypopharyngeal Carcinoma AJCC v7
• Stage IVB Laryngeal Cancer AJCC v7
• Stage IVB Major Salivary Gland Cancer AJCC v7
• Stage IVB Nasopharyngeal Carcinoma AJCC v7
• Stage IVB Oral Cavity Cancer AJCC v6 and v7
• Stage IVB Oropharyngeal Carcinoma AJCC v7

Intervention

Behavioral:
• Exercise Intervention
Participate in walking and/or strengthening program

Other:
• Health Telemonitoring
Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
• Health Telemonitoring
Use accelerometers, blood pressure monitor, weight scale, and smart phone
• Health Telemonitoring
Use smart phone
• Health Telemonitoring
Use CO monitor and smart phone
• Health Telemonitoring
Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies
• Health Telemonitoring
Use Fitbit and Actigraph

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Study completion (defined as completing the final assessment)		Up to 7 months after baseline
Primary	Physical Activity (PA) Assessment	PA will be measured by two different devices, (1) a consumer-grade wrist-worn device that collects continuous PA data (Fitbit), and (2) a research-grade, hip-worn accelerometer (Actigraph)	Up to 7 days
Primary	ECOG Performance Status	Eastern Cooperation Oncology Group (ECOG) is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record.	Up to 2 weeks
Secondary	Correlation between PA data from the Actigraph and Fitbit	Association between PA measured using a Fitbit and PA measured using Actigraph	Up to 7 days
Secondary	Correlation between patients' ECOG performance status scores and PA data	Association between performance status (PS) assesses by the patient's medical oncologist, and PA data	Up to 7 days
Secondary	Correlation between PA data and Overall Survivor (OS)	Association between Physical Activity (PA) data and the Overall Survivor (OS) rate	Up to 7 days
Secondary	Accrual of Diverse Sample of Cancer-Patients		Up to 2 weeks
Secondary	Retention of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.		Up to 2 weeks
Secondary	Acceptability of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.		Up to 2 weeks
Secondary	Participants ability to activate, set-up, and use the home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).		Up to 2 weeks
Secondary	Adherence to procedures for home-based health monitor devices activation (e.g. Fitbit, Actigraph, CO monitor, weight scales) self-monitoring (e.g. PA, weight), and self-reported data capture by the devices.		Up to 2 weeks
Secondary	Successful upload of data from the home-based health monitor devices to the Cyberinfrastructure for Comparative effectiveness Research (CYCORE) for future analysis.		Up to 2 weeks
Secondary	CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).		Up to 2 weeks

External Links

•   MD Anderson Cancer Center Website